AR100696A2 - Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas - Google Patents
Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogasInfo
- Publication number
- AR100696A2 AR100696A2 ARP150101727A ARP150101727A AR100696A2 AR 100696 A2 AR100696 A2 AR 100696A2 AR P150101727 A ARP150101727 A AR P150101727A AR P150101727 A ARP150101727 A AR P150101727A AR 100696 A2 AR100696 A2 AR 100696A2
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- oxo
- hydroxyl
- halogen
- prostaglandin compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000004043 oxo group Chemical group O=* 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 206010010774 Constipation Diseases 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000004423 acyloxy group Chemical group 0.000 abstract 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001721 carbon Chemical group 0.000 abstract 1
- 125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Uso de un compuesto 15-ceto-prostaglandina para fabricar una composición farmacéutica para tratar el estreñimiento inducido por drogas, en donde el compuesto 15-ceto-prostaglandina está representado por la fórmula general (1), en donde L, M y N son hidrógeno, hidroxilo, halógeno, alquilo inferior, hidroxialquilo (inferior) u oxo, en donde por lo menos uno de L y M es un grupo distinto de hidrógeno, y el anillo de cinco miembros puede tener por lo menos un enlace doble; A es -CH₂OH, -COCH₂OH, -COON o un derivado funcional del mismo; B es -CH₂-CH₂-, -CH=CH- o -CºC-; R¹ es un residuo hidrocarburo alifático medio o inferior bivalente saturado o no saturado que no es sustituido o es sustituido con halógeno, alquilo, hidroxilo, oxo, arilo o grupo heterocíclico y por lo menos un átomo de carbono en el hidrocarburo alifático es opcionalmente sustituido por oxígeno, nitrógeno o azufre; y Rᵃ es un residuo de hidrocarburo alifático medio o inferior saturado o no saturado, que no es sustituido o es sustituido con halógeno, oxo, hidroxilo, alcoxilo inferior, alcanoiloxilo inferior, cicloalquilo (inferior), cicloalquiloxilo (inferior), arilo, ariloxilo, grupo heterocíclico o grupo heterocíclico-oxilo. La composición obtenida posee una fuerte acción antagónica contra el estreñimiento inducido por drogas sin perder substancialmente el efecto principal de la droga.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28772001P | 2001-05-02 | 2001-05-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100696A2 true AR100696A2 (es) | 2016-10-26 |
Family
ID=23104042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101560A AR035237A1 (es) | 2001-05-02 | 2002-04-29 | Uso de un compuesto 15-cet-prostaglandina para fabricar una composicion para tratar estrenimiento inducido por drogas |
| ARP150101727A AR100696A2 (es) | 2001-05-02 | 2015-06-01 | Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020101560A AR035237A1 (es) | 2001-05-02 | 2002-04-29 | Uso de un compuesto 15-cet-prostaglandina para fabricar una composicion para tratar estrenimiento inducido por drogas |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6982283B2 (es) |
| EP (1) | EP1392318B1 (es) |
| JP (1) | JP4332353B2 (es) |
| KR (1) | KR100886598B1 (es) |
| CN (1) | CN1522147B (es) |
| AR (2) | AR035237A1 (es) |
| AT (1) | ATE355067T1 (es) |
| AU (1) | AU2002251554B2 (es) |
| BR (1) | BR0209327A (es) |
| CA (1) | CA2444103C (es) |
| DE (1) | DE60218451T2 (es) |
| DK (1) | DK1392318T3 (es) |
| ES (1) | ES2282408T3 (es) |
| MX (1) | MXPA03010019A (es) |
| NO (1) | NO335143B1 (es) |
| NZ (1) | NZ529187A (es) |
| PT (1) | PT1392318E (es) |
| TW (1) | TWI302100B (es) |
| WO (1) | WO2002089812A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1420794B1 (en) | 2001-08-31 | 2017-12-27 | Sucampo AG | Prostaglandin analogs as chloride channel openers |
| TWI331920B (en) | 2001-11-14 | 2010-10-21 | Sucampo Ag | Unit dosage form for relieving or treating constipation in human patients |
| TWI263505B (en) | 2001-11-19 | 2006-10-11 | Sucampo Ag | Pharmaceutical composition comprising a C1C-2 channel opener |
| NZ539582A (en) * | 2002-10-23 | 2007-07-27 | Sucampo Ag | Prostaglandin compounds for the treatment of obesity |
| EP1575596B1 (en) * | 2002-12-27 | 2016-06-22 | Sucampo AG | Derivatives of prostaglandins for treating irritable bowel syndrome and/or functional dyspepsia |
| TWI387454B (zh) * | 2004-09-02 | 2013-03-01 | 蘇坎波公司 | 治療胃腸道疾病之方法及組成物 |
| US8524731B2 (en) * | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| CN101171010B (zh) * | 2005-03-07 | 2014-09-17 | 芝加哥大学 | 阿片样物质拮抗剂用于减少内皮细胞增殖和迁移的用途 |
| US8962688B2 (en) * | 2005-04-12 | 2015-02-24 | Sucampo Ag | Method for the treatment of gastrointestinal disorders |
| US20090030072A1 (en) * | 2007-07-03 | 2009-01-29 | Sucampo Ag | Pharmaceutical combination of opioid and prostaglandin compound |
| US20090082442A1 (en) * | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched lubiprostone |
| US9044510B2 (en) | 2007-11-01 | 2015-06-02 | Washington University | Compositions and methods for treating pruritus |
| US9084815B2 (en) * | 2009-09-16 | 2015-07-21 | Sucampo Ag | Method for treating damage induced by an anti-tumor agent, treating mucositis and treating tumor |
| US8957024B2 (en) | 2011-07-27 | 2015-02-17 | Washington University | Composition and methods for reducing opioid-induced pruritus |
| KR20140052389A (ko) | 2012-10-24 | 2014-05-07 | 주식회사 아리바이오 | 해양 심층수 또는 염지하수로부터 제조된 고경도의 미네랄 워터를 포함하는 변비 예방, 개선 또는 치료용 조성물 |
| US20140116916A1 (en) | 2012-10-31 | 2014-05-01 | 2294719 Ontario Limited | Therapy for Constipation |
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| CN105777601A (zh) * | 2014-12-26 | 2016-07-20 | 中国人民解放军第二军医大学 | 一种前列地尔衍生物及其药物制剂 |
| EP3436011A4 (en) * | 2016-03-29 | 2019-12-04 | Colonaryconcepts LLC | FORMULATIONS FOR TREATING CONSTIPATION |
| US11534404B2 (en) | 2016-10-06 | 2022-12-27 | Sucampo Ag | Multilayer beads for pharmaceutical use |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1581886A (en) * | 1977-05-26 | 1980-12-31 | May & Baker Ltd | Prostanol derivatives |
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| ES2051862T3 (es) * | 1987-10-02 | 1994-07-01 | Ueno Seiyaku Oyo Kenkyujo Kk | Un metodo para producir un medicamento que tiene un efecto catartico. |
| US5317032A (en) | 1987-10-02 | 1994-05-31 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Prostaglandin cathartic |
| CA2027814C (en) * | 1989-10-20 | 1996-07-30 | Ryuji Ueno | Treatment of hepatobiliary disease with 15-keto-prostaglandin compounds |
| CA2039420C (en) | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
| DE69130586T2 (de) * | 1990-05-01 | 1999-06-17 | R-Tech Ueno, Ltd., Osaka | Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| PT857718E (pt) | 1996-06-10 | 2002-11-29 | Sucampo Ag | Antagonista da endotelina |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| BR0209863A (pt) * | 2001-05-18 | 2004-06-08 | Sucampo Ag | Composição catártica |
-
2002
- 2002-04-25 TW TW091108513A patent/TWI302100B/zh not_active IP Right Cessation
- 2002-04-26 BR BR0209327-8A patent/BR0209327A/pt not_active Application Discontinuation
- 2002-04-26 DE DE60218451T patent/DE60218451T2/de not_active Expired - Lifetime
- 2002-04-26 AT AT02720623T patent/ATE355067T1/de active
- 2002-04-26 NZ NZ529187A patent/NZ529187A/en not_active IP Right Cessation
- 2002-04-26 AU AU2002251554A patent/AU2002251554B2/en not_active Expired
- 2002-04-26 ES ES02720623T patent/ES2282408T3/es not_active Expired - Lifetime
- 2002-04-26 MX MXPA03010019A patent/MXPA03010019A/es active IP Right Grant
- 2002-04-26 EP EP02720623A patent/EP1392318B1/en not_active Expired - Lifetime
- 2002-04-26 KR KR1020037014221A patent/KR100886598B1/ko not_active Expired - Lifetime
- 2002-04-26 DK DK02720623T patent/DK1392318T3/da active
- 2002-04-26 JP JP2002586947A patent/JP4332353B2/ja not_active Expired - Fee Related
- 2002-04-26 CN CN028133897A patent/CN1522147B/zh not_active Expired - Lifetime
- 2002-04-26 CA CA2444103A patent/CA2444103C/en not_active Expired - Lifetime
- 2002-04-26 PT PT02720623T patent/PT1392318E/pt unknown
- 2002-04-26 WO PCT/JP2002/004223 patent/WO2002089812A1/en not_active Ceased
- 2002-04-29 AR ARP020101560A patent/AR035237A1/es not_active Application Discontinuation
- 2002-05-01 US US10/135,397 patent/US6982283B2/en not_active Expired - Lifetime
-
2003
- 2003-10-31 NO NO20034864A patent/NO335143B1/no not_active IP Right Cessation
-
2015
- 2015-06-01 AR ARP150101727A patent/AR100696A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CA2444103A1 (en) | 2002-11-14 |
| AU2002251554B2 (en) | 2007-05-24 |
| JP2004527567A (ja) | 2004-09-09 |
| EP1392318B1 (en) | 2007-02-28 |
| US20030073746A1 (en) | 2003-04-17 |
| KR20040008168A (ko) | 2004-01-28 |
| US6982283B2 (en) | 2006-01-03 |
| DE60218451D1 (de) | 2007-04-12 |
| ES2282408T3 (es) | 2007-10-16 |
| BR0209327A (pt) | 2004-07-20 |
| CN1522147A (zh) | 2004-08-18 |
| PT1392318E (pt) | 2007-05-31 |
| NO335143B1 (no) | 2014-09-29 |
| DE60218451T2 (de) | 2007-11-08 |
| JP4332353B2 (ja) | 2009-09-16 |
| TWI302100B (en) | 2008-10-21 |
| NO20034864L (no) | 2003-12-23 |
| WO2002089812A1 (en) | 2002-11-14 |
| DK1392318T3 (da) | 2007-06-25 |
| MXPA03010019A (es) | 2004-02-12 |
| CN1522147B (zh) | 2010-05-12 |
| NZ529187A (en) | 2005-10-28 |
| NO20034864D0 (no) | 2003-10-31 |
| AR035237A1 (es) | 2004-05-05 |
| KR100886598B1 (ko) | 2009-03-05 |
| EP1392318A1 (en) | 2004-03-03 |
| CA2444103C (en) | 2010-06-08 |
| ATE355067T1 (de) | 2006-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR100696A2 (es) | Uso de un compuesto de 15-ceto-prostaglandina para fabricar una composición para tratar estreñimiento inducido por drogas | |
| AR036391A1 (es) | Uso de un compuesto de prostaglandina para preparar una composicion farmaceutica para abrir los canales de cic en un mamifero y compuestos de prostaglandina | |
| MXPA06012595A (es) | Analogos de amino-tetrazoles y metodos de uso. | |
| NO20072435L (no) | CGRP-reseptorantagonister | |
| ECSP066298A (es) | Compuestos 1h-pirazol 3,4-disustituidos y su uso como moduladores de quinasas dependientes de ciclina (cdk) y quinasa-3 de sintasa de glicógeno (gsk-3) | |
| NO20076479L (no) | Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer | |
| FR2805817B1 (fr) | Compositions pharmaceutiques contenant des derives d'azetidine, les nouveaux derives d'azetidine et leur preparation | |
| EA200870521A1 (ru) | Замещенные спироциклические антагонисты cgrp-рецепторов | |
| NO20076478L (no) | Substituerte oksadiazolderivater som positive allosteriske modulatorer av metabotrope glutamatreseptorer | |
| PE20090610A1 (es) | Derivados de pirazol sustituidos | |
| UY28766A1 (es) | Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico | |
| NO20080875L (no) | Nye makrocykliske inhibitorer av hepatitt C virus replikasjon | |
| AR066962A1 (es) | Compuesto heterociclico fusionado | |
| AR036044A1 (es) | Compuestos piranoindazoles, composiciones farmaceuticas y su uso para la manufactura de un medicamento para el tratamiento del glaucoma | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| ATE503755T1 (de) | Cgrp-rezeptorantagonisten | |
| AR042670A1 (es) | Uso del abridor del canal de cloruro para preparar un compuesto farmaceutico para tratar el malestar abdominal | |
| WO2006008545A3 (en) | Thiazole and isothiazole derivatives as protein kinase inhibitors | |
| AR030275A1 (es) | Composicion que inhibe la apoptosis y uso de un compuesto 15-ceto-prostaglandina- para producirla | |
| CY1106713T1 (el) | Συνδυασμενη θεραπεια εναντιον καρκινωματων η οποια περιλαμβανει παραγωγα υποκαταστημενης ακρυλοϋλ δισταμυσινης και αλκυλιωτικους παραγοντες | |
| AR035242A1 (es) | Uso de un lipido bioactivo halogenadopara preparar una composicion catartica y compuesto lipido bioactivo halogenado | |
| ATE507880T1 (de) | Cgrp-rezeptorantagonisten | |
| PE20090822A1 (es) | DERIVADO DE 17ß-CIANO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE | |
| CO5150208A1 (es) | Compuestos de dihidropiridina ciclopentanona utiles como abridores de canales de potasio |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |